Resonant Capital Advisors LLC Grows Holdings in Becton, Dickinson and Company $BDX

Resonant Capital Advisors LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,904 shares of the medical instruments supplier’s stock after buying an additional 753 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,706,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of BDX. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company during the first quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company in the 1st quarter valued at $27,000. Cornerstone Planning Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $31,000. Finally, WPG Advisers LLC purchased a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $36,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX opened at $185.85 on Friday. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a 50 day moving average of $189.93 and a two-hundred day moving average of $183.97. The company has a market cap of $53.27 billion, a P/E ratio of 33.43, a P/E/G ratio of 1.45 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion for the quarter. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 1,838 shares of company stock valued at $348,392 over the last ninety days. 0.36% of the stock is owned by corporate insiders.

Analyst Ratings Changes

BDX has been the topic of several recent analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Piper Sandler reiterated a “neutral” rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Friday. Finally, Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.